Not to mention EU pharma makes 50-70% [1] of their money from the US, an unregulated market. I'd challenge them to shut down that 800USD/shot revenue stream and still give subsidised insulin locally and remain profitable. Hint: they can't. Their shareholders would shut them down in a week. Good luck manufacturing the next new drug then.

[1] https://www.novonordisk.com/content/dam/nncorp/global/en/inv... https://www.marketscreener.com/quote/stock/GSK-PLC-9590199/f...

Edit: I too agree the US healthcare system is flawed, I'm just saying you cannot compare it against EU's results without considering the above fact.